ACTO Named Luminary in Everest Group's Innovation Watch for 2026

ACTO Receives Luminary Recognition in Everest Group's Report

On October 5, 2026, ACTO announced its recognition as a Luminary in the Everest Group's Innovation Watch report focusing on Agentic AI in Life Sciences Commercial 2026. This accolade places ACTO among the top providers in the global assessment of agentic AI technologies catered to Life Sciences commercial teams.

The Everest Group's report evaluates 22 suppliers of agentic AI products and platforms across various metrics, including market performance and ecosystem factors like partnerships and investments. The suppliers are categorized into four groups: Luminaries, Fast Followers, Influencers, and Seekers. ACTO has distinguished itself within the Luminary category, recognized for its outstanding market performance and dynamic role in advancing its ecosystem.

As agentic AI continues to play a pivotal role in transforming business operations within the Life Sciences sector, the report highlights significant opportunities across sales, marketing, medical affairs, market access, and patient services. Companies are increasingly leveraging agentic AI to enhance decision-making, automate repetitive tasks, seamlessly coordinate actions across different systems, and deliver more personalized interactions.

Rohit K, Practice Director at Everest Group, remarked, "As Life Sciences companies harness agentic AI across their commercial functions, the focus shifts from isolated AI applications to interconnected commercial platforms. These platforms are crucial for linking data, content, and workflows across roles and systems. The effectiveness of agentic AI will rely heavily on its ability to harmonize activities between systems and functions while maintaining governance, traceability, and human accountability."

ACTO stands out due to its role-based agentic AI approach tailored for the commercial Life Sciences sector, integrating domain-specific SuperAgents with a multi-platform orchestration and governance focused on Life Sciences. The company’s growing partner ecosystem and early deployments among clients position it as a leader in this space, which ultimately led to its Luminary status in the aforementioned report.

The development of ACTO's integration ties back to a well-planned AI strategy the company has been cultivating for several years. Initiating investments in AI back in 2022 with the launch of LAICA—its IA-based conversational assistant dedicated to education in Life Sciences—led to the introduction of ACTO SuperAgents in 2026. Parth Khanna, co-founder and CEO of ACTO, expressed, "We are thrilled to be recognized as a Luminary by Everest Group, alongside our strategic partners, Veeva and Salesforce. Our ongoing investment in agentic AI stems from our belief that AI can deeply transform the way work is conducted in Life Sciences, not by replacing people but by enabling them to work more efficiently. This vision is now a reality."

Clients increasingly recognize the substantial value brought by ACTO's role-based SuperAgents, designed to understand both the individual, their tasks, and the highly regulated environment in which they operate. This acknowledgment reinforces ACTO's belief that the future of AI in Life Sciences lies not in an abundance of tools but in crafting an intelligent, connected work environment where humans and AI collaborate to yield better outcomes.

ACTO's exclusive focus on the Life Sciences sector composes its AI-powered Field Excellence platform and specialized role-based SuperAgents. These elements support systems integration, facilitating real-time, compliant assistance—from clinical and scientific information retrieval to fielding medical queries—allowing client-facing professionals to spend less time navigating systems and more time fostering relationships with healthcare providers.

This recognition follows ACTO’s earlier inclusion in the Top 50™ Pharmaceutical Technology Providers for 2026 by the Everest Group, further underlining the company's unwavering commitment to delivering field excellence through AI tailored for the Life Sciences sector.

For further insights into ACTO's role-based SuperAgents, interested parties can download a free copy of the report at acto.com/superagents. To stay updated on ACTO's latest developments, visit acto.com and follow their LinkedIn page.

About Everest Group

Everest Group is a premier global research firm that assists business leaders in making informed decisions. Their PEAK Matrix® assessments provide organizations with analysis and insights necessary for making critical decisions about global service providers, locations, products, and solutions across diverse market segments.

About ACTO

Trusted by 14 of the 50 largest pharma companies, fast-growing biotech firms, and leading medical technology organizations, ACTO is redefining how therapies reach patients after regulatory approval. By merging human intelligence with empathetic AI, ACTO’s field excellence platform and specialized AI SuperAgents accelerate product launches, enhance field execution, and deepen customer engagement. By streamlining training and coaching while identifying up to 30% of routine tasks for client-facing roles, ACTO empowers teams to focus on what truly matters: human relationships, judgment, and strategic execution. ACTO adheres to the highest industry regulatory standards, validated for compliance with 21 CFR Part 11 and certified SOC 2 Type II. Learn more at acto.com.